TAIZHOU, Jiangsu Province, China, June 19 /Xinhua-PRNewswire/ -- Shenzhen Beike Biotechnology Co., Ltd. ( http://www.beikebiotech.com ), a worldwide leader in providing safe and effective stem cell applications for medical treatment, has commenced outfitting its 21,500 square foot comprehensive medical stem cell storage and processing facility in eastern China. When fully completed, the Jiangsu Stem Cell Storage Facility will be one of the most highly developed of its kind anywhere in the world, with advanced technology and safe conditions to properly freeze, store, and process a broad range of human stem cell samples for clinical application. The Stem Cell Storage Facility will initially provide stem cell banking for human umbilical cord blood stem cells, placenta stem cells, amniotic membrane stem cells, bone marrow stem cells, and later will also be able to house induced pluripotent stem cells (iPS). Considered the future for stem cell treatments, iPS cells are derived from cell reprogramming technologies and are a non-controversial potential alternative to embryonic stem cells. Like umbilical cord blood stem cells, iPS cells can be preserved for later use in fighting a range of disorders.
Initially, the facility will be used primarily for private banking of stem cells by individuals, but as the number of samples increases, it will focus on public banking for medical facilities with the aim of allowing Beike to become a global supplier for patients in need of stem cell transplants. Jiangsu Beike Biotechnology Co., Ltd., a subsidiary of Shenzhen Beike Biotechnology Co., Ltd., has been established to manage the facility.
Dr. Sean Hu, the Chairman of Beike Biotech said, "Stem cell storage is
the next logical step for us given our years of experience in handling and
culturing stem cells to successfully treat patients from all over the
world. With this groundbreaking new storage facility, Bei
|SOURCE Shenzhen Beike Biotechnology Co., Ltd.|
Copyright©2008 PR Newswire.
All rights reserved